Table 3.

Disease control by HER2 mutation status in the pooled immunotherapy cohort.

Therapy and DC*	Wild-type (%)	Mutation (%)	P value
Anti-CTLA-4
PD	79 (60.3)	5 (50.0)	0.522
DC	52 (39.7)	5 (50.0)
Anti-PD-1/-PD-L1
PD	60 (38.7)	1 (12.5)	0.135
DC	95 (61.3)	7 (87.5)
All
PD	144 (48.6)	6 (33.3)	0.207
DC	152 (51.4)	12 (66.7)

^* Response data were available in 314 patients.

DC, disease control (defined as response or stable disease); PD, progressed disease.